New drug combo shows promise for kidney disease in small trial
NCT ID NCT05834738
First seen Jan 31, 2026 · Last updated Jun 11, 2026 · Updated 20 times
Summary
This study tested whether adding the drug atrasentan to standard care (including SGLT2 inhibitors) can reduce protein in the urine of people with IgA nephropathy, a kidney disease. 54 adults with biopsy-confirmed IgA nephropathy participated. The main goal was to see if atrasentan lowers proteinuria more than placebo over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chung-Ang University College
Seoul, Seoul, 06973, South Korea
-
Dong-A University Medical Center (Dong-A University Hospital)
Busan, Busan, 49201, South Korea
-
Fides Clinical Research
Atlanta, Georgia, 30342, United States
-
Hallym University Sacred Heart Hospital
Anyang-si, Gyeonggi-do, 14068, South Korea
-
Hopsital Sultanah Aminah Johor Bharu (HSAJB) - Bangunan Bakawali Heodialysis Centre
Johor Bahru, Johor Darul Takzim, 80100, Malaysia
-
Hospital 12 de Octubre
Madrid, 28041, Spain
-
Hospital Clinico Universitario
Valencia, 46010, Spain
-
Hospital Raja Permaisuri Bainun (HRPB)
Ipoh, Perak, 30450, Malaysia
-
Hospital Ribera Polusa
Lugo, 27004, Spain
-
Hospital Torrecardenas
Almería, 04009, Spain
-
Hospital Universitario De Getafe (HUG)
Madrid, 28009, Spain
-
Hospital Virgen Macarena
Seville, 41009, Spain
-
Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, São Paulo, 05403-000, Brazil
-
Hospital del Mar
Barcelona, 08003, Spain
-
Hospital del Vall d´Hebron
Barcelona, 08035, Spain
-
Monash Health- Monash Medical Centre
Melbourne, Victoria, 3168, Australia
-
NANI Research
Oak Brook, Illinois, 60523, United States
-
NUPEC Cardio
Belo Horizonte, Minas Gerais, 30220-140, Brazil
-
Prince of Wales Hospital
Sydney, New South Wales, 2031, Australia
-
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-074, Brazil
-
Soon Chun Hyang Central Medical Center (SCHMC) - Soon Chun Hyang University Hospital
Cheonan, Chungnam-Do, 31151, South Korea
-
Sunshine Hospital
St Albans, Victoria, 3021, Australia
-
The St. George Hospital
Kogarah, New South Wales, 2217, Australia
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
Universidade Federal de Sao Paulo
São Paulo, São Paulo, 04038-002, Brazil
-
Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))
Cheras, Kuala Lumpur, 56000, Malaysia
-
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, 59100, Malaysia
-
University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Nephrology Clinic
Birmingham, Alabama, 35233, United States
-
University of North Carolina at Chapel Hill - Nephrology and Hypertension
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.